Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Non-Current Liabilities (2023 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $60.7 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 21.77% to $60.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.7 million through Dec 2025, up 21.77% year-over-year, with the annual reading at $60.7 million for FY2025, 21.77% up from the prior year.
  • Total Non-Current Liabilities hit $60.7 million in Q4 2025 for Eton Pharmaceuticals, down from $77.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $77.4 million in Q3 2025 to a low of $16.3 million in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $55.5 million across 3 years, with a median of $58.1 million in 2025.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 206.62% in 2024 and later increased 21.77% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $16.3 million in 2023, then surged by 206.62% to $49.9 million in 2024, then grew by 21.77% to $60.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ETON at $60.7 million in Q4 2025, $77.4 million in Q3 2025, and $73.4 million in Q2 2025.